Thanks @708 to the tag and heads up keeping others informed and...

Thanks @708 to the tag and heads up keeping others informed and up to date...

its slowly changing here in Australia, yet people power will change to what prescribed plant medicine of choice they would like administered...

i was pondering the notion of Dr Meiri research and be good to hear an update to Multiple Sclerosis human trails to cannabis efficiency, effectiveness, safety dosage usage and which Cannabinoids strains have the most efficacy to treat MS.

Identifying cannabinoids types, strains analyses and metabolomics to specific chemical composition of cannabis plants with the abilities to comprehensively profiling Cannabinoids compositions of varieties in cannabis strains to be able to single out which Phyto Cannabinoids Crete examination in different types of studies and cannabinoids in discovery, like for example….

Cannabis chemical composition analyses current focus on identifying and quantifying several major Cannabinoids types including THC, CBD and in some recent studies also Cannbichromene (CGC) Cannabinol (CBN) and Cannaligerol (CBG) and other cannabis compounds which may be important to their therapeutic effects that have been predominantly neglected, for example….

Cannabigerols (CBG)
Cannabichromenes (CBC)
Cannabidiols (CBD)
Tetrahydrocannabinols (THC)
Cannabinol (CBN)
Cannabinodiol (CBDL)
Cannabicyclol (CBL)
Cannabielsoin (CBE)
Cannabitriol (CBT)
Cannabivarin (CBV)
Tetrahydrocannabivarin (THCV)
Cannabidivarin (CBDV)
Cannabichromevarin (CBCV)
Cannabigerovarin (CBGV)
Cannabigerol Monoethyl Ether (CBGM)
Tetrahydrocannabiphorol (THCP)
Cannabidiphorol (CBDP).

Considering the latest update announcement on February 3rd 2020 quartley report in medical research and treatment to Multiple Sclerosis from pre clinical trails from mice trails into human trails to either halt progression or assist recovery from particular cannabis species strains of cannabis working efficiently and effectively with safety which are currently being undertaking by Professor Meiri at Technion Haifa in Israel in human trials which are currently being coordinated in Israel together with Israel’s leading hospitals.

It’s a long process from pre clinic mice trials to stage 1 or phase 1 clinical trails which involves first administration to humans to safety and tolerance, usually to small number of patients or volunteers with exploring cannabis metabolism and interactions, administration of micro dosages and or multiple dosages, which data is retrieved, analysed, which cannabis strains, chemical compositions are working etc..

With data retrieved from phase 1 moves into Phase 2 for efficacy and safety which may be undertaken in larger groups of human patients and may involve several hundred patients to demonstrate biological activity through pilot studies in phase 1, therapeutic range dosage and optimum dosage for efficacy and safety and resolving uncertainties regarding the design of conduct of subsequent trail…

This leads me to believe after 18 months more or less, Dr Meiri and his team are in most critical stage, which will be phase 3.

Phase 3 there must be therapeutic safety dosages. efficacy, effectiveness, from pre clinical mice trails into human trails from micro dosages and or multiple dosages, which usually involves a large group of patients from several hundred to several thousand to determine the therapeutic effect in patient populations for which the cannabis is eventually intended, providing definitive assessment of risk-benefit balance to support cannabis registration or change in clinical practice and increase patient exposure and support marketing claims or publication claims in supporting cannabis chemical compounds and plant species strains effectiveness efficacy and safety.

So in my opinion the longer the wait in trail 3 phase/stage the better results determining cannabis efficacy, safety and effectiveness in many humans affected with Multiple Sclerosis, dosage usage and which Cannabinoids have the most efficacy to treat Multiple Sclerosis.

So technically the longer the wait in stage 3 into stage 4 the better the data effectiveness and safety to multiple sclerosis dosage usage, yet have to admit and update would great to hear to where the research is at..

Stage 4 is the easier path, receiving data to what is working with recommendations from Higher Authorities, Pharmaceuticals Authorities, TGA approvals and any other authority that can be determined from human trails, studies and to distributions to post marketing treatments in the real world populations in Pharmacoeconomics supporting the evidence base research with comparative effectiveness to the community trail combinations with existing product…

I personally don’t believe their will be cure (yet anything is possible to halt progression or assist recovery ) yet I do believe treatment will alleviate pain in dosage formulation to humans, as every human will have differences in metabolism biochemical process, physiology, etc, as every human is different, yet too alleviate or relive pain that is safe to provide a better healthier lifestyle.

Yet what matters most by the end of phase 3 trails and before the end of 2020, that Dr Meiri research in Technion Haifa in Israel know which and what cannabinoids strains and dosages are working better than anything currently on the market and the research to provide achieved and promising results with facts and evidence data to support cannabis efficacy, safety dosage and effectiveness in many humans affected with Multiple Sclerosis and with unique cannabinoids formulations in succession , then CGB will have a game changer on their hands..

And those hemp cigars will be my treat with best wishes too many other CGB holders…